Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A1chieve study
References (22)
- et al.
IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030
Diabetes Res Clin Pract
(2011) - et al.
An observational non-interventional study of patients with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study
Diabetes Res Clin Pract
(2011) - et al.
Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin
J Diabetes Complications
(2003) - et al.
Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update
Nutr Metab Cardiovasc Dis
(2006) - et al.
A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study
Endocr Pract
(2011) - et al.
Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: Results from the A(1)chieve study
Diabetes Res Clin Pract
(2012) - International Diabetes Federation. IDF Diabetes Atlas. 5th ed. Brussels, Belgium; 2011, updated 14 November...
- et al.
DiabCare Algérie
Médecine des maladies Métaboliques
(2010) - et al.
Improving care and prevention for people with diabetes in Algeria
Diabetes Voice
(2008) - et al.
Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings
Drugs
(2012)
Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs
Diabetes Care
(2005)
Cited by (1)
Drug-related risk of severe hypoglycaemia in observational studies: A systematic review and meta-analysis
2015, BMC Endocrine Disorders
Copyright © 2013 Elsevier Ireland Ltd. Published by Elsevier Ireland Ltd. All rights reserved.